Tuesday, May 19, 2020

Trump Takes ‘Historic’ Action To Move Pharmaceutical Manufacturing Out Of China, Back To U.S.

 An employee holds Ramipril capsules for a photograph inside a coating unit at the Lupin Ltd. pharmaceutical plant in Salcette, Goa, India, on Friday, Feb. 7, 2014. Lupin, founded by billionaire Desh Bandhu Gupta, expects to gain share in the U.S. amid increased regulatory oversight and curbs on competitors including Ranbaxy Laboratories Ltd.

In an “historic turning point,” the Trump administration has taken bold action to bring America’s pharmaceutical manufacturing back to the U.S. from China and India.

“Seeking to secure the nation’s supply of critical medications, the Trump administration has signed a $354 million contract that would create the nation’s first strategic stockpile of key ingredients needed to make medicines,” NBC News reported. “The agreement was signed Monday with Phlow Corp., a generic drug maker based in Virginia.”

No comments:

Post a Comment